Two ways to prepare the womb for frozen embryo transfer in female infertility
Compares two ways of preparing the womb for frozen embryo transfer in infertile women.
Key facts
- Who runs it
- Shandong University of Traditional Chinese Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Progesterone-modified Natural Cycle for FET
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 336 people, planned
- Started
- 5 Mar 2025
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Progesterone-modified natural cycle preparation for frozen embryo transfer
- Hormone replacement therapy cycle preparation for frozen embryo transfer
- Record updated
- 29 April 2026
Who can take part
The trial is looking for women aged 21 to 44 with regular ovulation who are having a single frozen blastocyst (embryo) transfer. It compares two ways of preparing the womb lining.
- Age
- 21 to 44 years
- Sex
- Women only
- Disease stage
- Female infertility, with regular ovulatory cycles. Body mass index (BMI) 18-35 kg/m2.
- Earlier treatment
- People who had more than 2 failed embryo transfers cannot join.
- Main reasons for not taking part
- Untreated scar tissue (adhesions) inside the womb
- Medical reasons that rule out estrogen and progesterone treatment
- Illnesses that rule out assisted reproduction or pregnancy
- Repeated implantation failure (> 2 embryo transfer failures)
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Patients aged 21 to 44 years undergoing FBT
- Body mass index (BMI) 18-35 kg/m2
- Having regular ovulatory cycles
Who cannot take part
- Medical contraindications to estrogen and progesterone therapy
- Illnesses contraindicating assisted reproductive technology or pregnancy
- History of recurrent implantation failures (> 2 embryo transfer failures)
- Untreated uterine adhesions
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Female infertility
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hormone replacement therapy (HRT) cycles, despite the ease of synchronizing embryo thawing and embryo transfer timing, increase the risk of pregnancies and obstetric complications compared to natural cycles (NC). By ensuring the presence of the corpus luteum while reducing the number of monitoring sessions, the progesterone modified natural cycle (P4mNC) offers more convenience for the patient than the normal NC. This study is designed to compare the effects of P4mNC and HRT cycles on FET outcomes.
The 2 groups in the trial
- P4mNC groupTreatment being tested
On days 8-12 of the menstrual cycle (MC), depending on the length of the patient's MC, transvaginal ultrasound is used to monitor follicular development and endometrial growth. Vaginal micronized progesterone (Utrogestan, Besins, Belgium) is started at 200 mg in the afternoon and 200 mg in the evening when the dominant follicle reached ≥16 mm and the endometrial thickness is at least 7 mm. A blastocyst is transferred on day 5 after the addition of progesterone. On day 14 after blastocyst transfer, serum β-hCG levels are measured. Upon positive serum pregnancy testing, progesterone support will continue until 8-10 weeks of gestation. However, afternoon progesterone use is eliminated for 30 days after embryo transfer.
Treatment: Progesterone-modified natural cycle preparation for frozen embryo transfer
- HRT groupExisting treatment, for comparison
Endometrial preparation will begin on the second day of the menstrual cycle with oral estradiol (E2) valerate at a dose of 2 mg twice daily. When the patient's endometrial thickness is ≥7 mm, vaginal progesterone administration will be initiated at a dose of 200 mg 3 times daily. On day 5 of the progesterone administration, blastocysts are thawed and transferred. For patients with endometrial thickness \<7 mm, patients continued oral E2 until the endometrium is ≥7 mm. On day 14 after blastocyst transfer, serum β-hCG levels are measured. Upon positive serum pregnancy testing, E2 and progesterone supplementation is continued for 8-10 weeks of gestation.
Treatment: Hormone replacement therapy cycle preparation for frozen embryo transfer
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Progesterone-modified Natural Cycle and Hormone Replacement Therapy Cycle for Endometrial Preparation in Single Frozen Blastocyst Transfer
- Plain-language title
- Two ways to prepare the womb for frozen embryo transfer in female infertilityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06644794, who can take part
- Record updated
- 29 April 2026